| Survivors without events (N = 32) | Survivors with events (N = 24) | Nonsurvivors (N = 28) | P | |
| Age, years | 65 ±14 | 68 ±10 | 74 ±8 | 0.01 |
| Men | 21 (66%) | 13 (54%) | 15 (54%) | 0.57 |
| Medical history | ||||
| Ischemic heart disease | 13 (41%) | 4 (17%) | 13 (46%) | 0.06 |
| Atrial fibrillation | 7 (23%) | 12 (50%) | 10 (36%) | 0.11 |
| Left ventricular ejection fraction, % | 51 ±16 | 59 ±16 | 49 ±23 | 0.10 |
| eGFR, ml/min/1.73 m2 | 66±19 | 60 ±18 | 46 ±21 | 0.01 |
| Diabetes mellitus | 5 (16%) | 6 (25%) | 12 (43%) | 0.06 |
| Hypertension | 18 (56%) | 10 (42%) | 12 (43%) | 0.46 |
| Current smoker | 7 (22%) | 9 (38%) | 8 (30%) | 0.44 |
| Medications | ||||
| Beta-blocker | 13 (41%) | 10 (42%) | 7 (25%) | 0.35 |
| ACE inhibitor/ARB | 21 (66%) | 11 (46%) | 16 (57%) | 0.33 |
| Brain natriuretic peptide, pg/ml | 145 ±25 | 222 ±43 | 357 ±65 | <0.01 |
| Left ventricular morphology | ||||
| End-diastolic volume index, ml/m2 | 86 ±28 | 87 ±27 | 89 ±36 | 0.90 |
| End-systolic volume index, ml/m2 | 45 ±28 | 38 ±22 | 49 ±33 | 0.34 |
| Mass index, g/m2 | 143 ±35 | 142 ±45 | 139 ±50 | 0.94 |